S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
OTCMKTS:ADXS

Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News

$1.20
+0.20 (+20.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.10
$1.20
50-Day Range
$0.65
$1.29
52-Week Range
$0.65
$7.20
Volume
16,264 shs
Average Volume
7,660 shs
Market Capitalization
$2.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADXS stock logo

About Ayala Pharmaceuticals (OTCMKTS:ADXS) Stock

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
Armando Ayala
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
Ayala Pharmaceuticals, Inc. (ADXS)
Hubei Biocause Pharmaceutical
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Company Calendar

Last Earnings
9/09/2021
Today
6/01/2023
Next Earnings (Estimated)
6/06/2023
Fiscal Year End
10/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ADXS
Employees
14
Year Founded
2002

Profitability

Net Income
$-14,360,000.00
Pretax Margin
-5,723.60%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
$13.01 per share

Miscellaneous

Free Float
1,810,000
Market Cap
$2.18 million
Optionable
Optionable
Beta
2.44

Social Links


Key Executives

  • Ken Berlin
    President, Chief Executive Officer & Director
  • Igor Gitelman
    VP-Finance, Chief Financial & Accounting Officer
  • Andres A. Gutiérrez
    Chief Medical Officer & Executive Vice President
  • Michael Grace
    Vice President-Technical Operations













ADXS Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADXS shares.
View ADXS analyst ratings
or view top-rated stocks.

How have ADXS shares performed in 2023?

Ayala Pharmaceuticals' stock was trading at $1.20 on January 1st, 2023. Since then, ADXS shares have increased by 0.0% and is now trading at $1.20.
View the best growth stocks for 2023 here
.

Are investors shorting Ayala Pharmaceuticals?

Ayala Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,200 shares, an increase of 73.3% from the April 30th total of 3,000 shares. Based on an average daily trading volume, of 12,900 shares, the days-to-cover ratio is presently 0.4 days.
View Ayala Pharmaceuticals' Short Interest
.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023.
View our ADXS earnings forecast
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) issued its quarterly earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biotechnology company had revenue of $0.25 million for the quarter.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS."

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of ADXS stock can currently be purchased for approximately $1.20.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.18 million and generates $3.24 million in revenue each year. The biotechnology company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (OTCMKTS:ADXS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -